Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop
β-cell replacement therapy, available currently as pancreas or islet transplantation, has developed without a clear definition of graft functional and clinical outcomes. The International Pancreas and Islet Transplant Association and European Pancreas and Islet Transplantation Association held a wor...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Lippincott, Williams & Wilkins
2018
|
| _version_ | 1797069085341646848 |
|---|---|
| author | Rickels, MR Stock, PG De Koning, EJP Piemonti, L Pratschke, J Alejandro, R Bellin, MD Berney, T Choudhary, P Johnson, PR Kandaswamy, R Kay, TWH Keymeulen, B Kudva, YC Latres, E Langer, RM Lehmann, R Ludwig, B Markmann, JF Marinac, M Odorico, JS Pattou, F Senior, PA Shaw, JAM Vantyghem, M-C White, S |
| author_facet | Rickels, MR Stock, PG De Koning, EJP Piemonti, L Pratschke, J Alejandro, R Bellin, MD Berney, T Choudhary, P Johnson, PR Kandaswamy, R Kay, TWH Keymeulen, B Kudva, YC Latres, E Langer, RM Lehmann, R Ludwig, B Markmann, JF Marinac, M Odorico, JS Pattou, F Senior, PA Shaw, JAM Vantyghem, M-C White, S |
| author_sort | Rickels, MR |
| collection | OXFORD |
| description | β-cell replacement therapy, available currently as pancreas or islet transplantation, has developed without a clear definition of graft functional and clinical outcomes. The International Pancreas and Islet Transplant Association and European Pancreas and Islet Transplantation Association held a workshop to develop consensus for an International Pancreas and Islet Transplant Association and European Pancreas and Islet Transplant Association Statement on the definition of function and failure of current and future forms of β-cell replacement therapy. There was consensus that β-cell replacement therapy could be considered as a treatment for β-cell failure, regardless of etiology and without requiring undetectable C-peptide, accompanied by glycemic instability with either problematic hypoglycemia or hyperglycemia. Glycemic control should be assessed at a minimum by glycated hemoglobin (HbA1c) and the occurrence of severe hypoglycemia. Optimal β-cell graft function is defined by near-normal glycemic control (HbA1c ≤6.5% [48 mmol/mol]) without severe hypoglycemia or requirement for insulin or other antihyperglycemic therapy, and with an increase over pretransplant measurement of C-peptide. Good β-cell graft function requires HbA1c less than 7.0% (53 mmol/mol) without severe hypoglycemia and with a significant (>50%) reduction in insulin requirements and restoration of clinically significant C-peptide production. Marginal β-cell graft function is defined by failure to achieve HbA1c less than 7.0% (53 mmol/mol), the occurrence of any severe hypoglycemia, or less than 50% reduction in insulin requirements when there is restoration of clinically significant C-peptide production documented by improvement in hypoglycemia awareness/severity, or glycemic variability/lability. A failed β-cell graft is defined by the absence of any evidence for clinically significant C-peptide production. Optimal and good function are considered successful clinical outcomes. |
| first_indexed | 2024-03-06T22:19:20Z |
| format | Journal article |
| id | oxford-uuid:547e3e35-748d-47da-bb3f-a396174edf3e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:19:20Z |
| publishDate | 2018 |
| publisher | Lippincott, Williams & Wilkins |
| record_format | dspace |
| spelling | oxford-uuid:547e3e35-748d-47da-bb3f-a396174edf3e2022-03-26T16:38:13ZDefining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshopJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:547e3e35-748d-47da-bb3f-a396174edf3eEnglishSymplectic Elements at OxfordLippincott, Williams & Wilkins2018Rickels, MRStock, PGDe Koning, EJPPiemonti, LPratschke, JAlejandro, RBellin, MDBerney, TChoudhary, PJohnson, PRKandaswamy, RKay, TWHKeymeulen, BKudva, YCLatres, ELanger, RMLehmann, RLudwig, BMarkmann, JFMarinac, MOdorico, JSPattou, FSenior, PAShaw, JAMVantyghem, M-CWhite, Sβ-cell replacement therapy, available currently as pancreas or islet transplantation, has developed without a clear definition of graft functional and clinical outcomes. The International Pancreas and Islet Transplant Association and European Pancreas and Islet Transplantation Association held a workshop to develop consensus for an International Pancreas and Islet Transplant Association and European Pancreas and Islet Transplant Association Statement on the definition of function and failure of current and future forms of β-cell replacement therapy. There was consensus that β-cell replacement therapy could be considered as a treatment for β-cell failure, regardless of etiology and without requiring undetectable C-peptide, accompanied by glycemic instability with either problematic hypoglycemia or hyperglycemia. Glycemic control should be assessed at a minimum by glycated hemoglobin (HbA1c) and the occurrence of severe hypoglycemia. Optimal β-cell graft function is defined by near-normal glycemic control (HbA1c ≤6.5% [48 mmol/mol]) without severe hypoglycemia or requirement for insulin or other antihyperglycemic therapy, and with an increase over pretransplant measurement of C-peptide. Good β-cell graft function requires HbA1c less than 7.0% (53 mmol/mol) without severe hypoglycemia and with a significant (>50%) reduction in insulin requirements and restoration of clinically significant C-peptide production. Marginal β-cell graft function is defined by failure to achieve HbA1c less than 7.0% (53 mmol/mol), the occurrence of any severe hypoglycemia, or less than 50% reduction in insulin requirements when there is restoration of clinically significant C-peptide production documented by improvement in hypoglycemia awareness/severity, or glycemic variability/lability. A failed β-cell graft is defined by the absence of any evidence for clinically significant C-peptide production. Optimal and good function are considered successful clinical outcomes. |
| spellingShingle | Rickels, MR Stock, PG De Koning, EJP Piemonti, L Pratschke, J Alejandro, R Bellin, MD Berney, T Choudhary, P Johnson, PR Kandaswamy, R Kay, TWH Keymeulen, B Kudva, YC Latres, E Langer, RM Lehmann, R Ludwig, B Markmann, JF Marinac, M Odorico, JS Pattou, F Senior, PA Shaw, JAM Vantyghem, M-C White, S Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop |
| title | Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop |
| title_full | Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop |
| title_fullStr | Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop |
| title_full_unstemmed | Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop |
| title_short | Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop |
| title_sort | defining outcomes for β cell replacement therapy in the treatment of diabetes a consensus report on the igls criteria from the ipita epita opinion leaders workshop |
| work_keys_str_mv | AT rickelsmr definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT stockpg definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT dekoningejp definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT piemontil definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT pratschkej definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT alejandror definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT bellinmd definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT berneyt definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT choudharyp definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT johnsonpr definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT kandaswamyr definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT kaytwh definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT keymeulenb definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT kudvayc definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT latrese definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT langerrm definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT lehmannr definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT ludwigb definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT markmannjf definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT marinacm definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT odoricojs definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT pattouf definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT seniorpa definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT shawjam definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT vantyghemmc definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop AT whites definingoutcomesforbcellreplacementtherapyinthetreatmentofdiabetesaconsensusreportontheiglscriteriafromtheipitaepitaopinionleadersworkshop |